Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI Clot)

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 7, 2011, Pages 1696-1702

  Gajos, Grzegorz ^a,b,c   Zalewski, Jaroslaw ^a,c   Rostoff, Pawel ^a   Nessler, Jadwiga ^a,c   Piwowarska, Wiesława ^a   Undas, Anetta ^b,c  

^a Department of Coronary Disease ^*  (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

angioplasty; fibrin; fish oils; oxidative stress; thrombin

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; FIBRINOGEN; OMEGA 3 FATTY ACID; PLACEBO; PROTHROMBIN; THROMBIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOGENESIS; TREATMENT DURATION;

AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; BIOLOGICAL MARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DINOPROST; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; FIBRIN; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLAND; PROSPECTIVE STUDIES; PROTHROMBIN; THROMBIN; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959760769     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.228593     Document Type: Article

References (35)

1. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-2945.
2. Gurbel PA, Bliden KP, Guyer K, Aggarwal N, Tantry US. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res. 2007;119:563-570. (Pubitemid 46321504)
3. Fatah K, Hamsten A, Blomback B, Blomback M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins, and coronary atherosclerosis. Thromb Haemost. 1992;68:130-135.
4. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26: 2567-2573. (Pubitemid 44607482)
5. Beygui F, Collet J-P, Nagaswami C, Weisel JW, Montalescot G. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction: time makes the difference. Circulation. 2006;113:e21-e23.
6. Marek G, Kablak-Ziembicka A, Stepien E, Undas A. Architecture of the thrombi removed from coronary artery bypass grafts in a patient with acute myocardial infarction. J Thromb Thrombolysis. 2010;30:372-374.
7. Undas A, Szułdrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, Pasowicz M, Zmudka K. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2008;196:551-557.
8. Zalewski J, Undas A, Godlewski J, Stepien E, Zmudka K. No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler Thromb Vasc Biol. 2007;27:2258-2265. (Pubitemid 350287258)
9. Undas A, Zalewski J, Krochin M, Siudak Z, Sadowski M, Pregowski J, Dudek D, Janion M, Witkowski A, Zmudka K. Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol. 2010;30:276-282.
10. Patel JV, Tracey I, Hughes EA, Lip GY. Omega-3 polyunsaturated acids and cardiovascular disease: notable ethnic differences or unfulfilled promise? J Thromb Haemost. 2010;8:2095-2104.
11. Vanschoonbeek K, Wouters K, van der Meijden PE, van Gorp PJ, Feijge MA, Herfs M, Schurgers LJ, Hofker MH, de Maat MP, Heemskerk JW. Anticoagulant effect of dietary fish oil in hyperlipidemia: a study of hepatic gene expression in APOE2 knock-in mice. Arterioscler Thromb Vasc Biol. 2008;28:2023-2029.
12. Nordoy A, Bonaa KH, Sandset PM, Hansen JB, Nilsen H. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol. 2000;20:259-265. (Pubitemid 30048373)
13. Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, Lawrence A, DeVine D, Lau J. Effects of Omega-3 Fatty Acids on Cardiovascular Risk Factors and Intermediate Markers of Cardiovascular Disease. Evid Rep Technol Assess (Summ). AHRQ Publication No. 04-E010-2. Rockville, MD: Agency for Healthcare Research and Quality; 2004;93:1-6.
14. Vanschoonbeek K, Feijge MA, Paquay M, Rosing J, Saris W, Kluft C, Giesen PL, de Maat MP, Heemskerk JW. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol. 2004;24:1734-1740. (Pubitemid 39180903)
15. Barcelli U, Glas-Greenwalt P, Pollak VE. Enhancing effect of dietary supplementation with omega-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res. 1985;39:307-312. (Pubitemid 15240334)
16. Lee KW, Blann AD, Lip GY. Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res. 2006;118:305-312. (Pubitemid 44067196)
17. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI study. J Am Coll Cardiol. 2010;55:1671-1678.
18. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood. 2001;98:2423-2431.
19. Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, Kearney MT, Ariens RA, Grant PJ. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol. 2009;29:712-717.
20. Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P, Johnston M, Yusuf S. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2002;23:1771-1779. (Pubitemid 35334270)
21. Undas A, Stepień E, Branicka A, Wołkow P, Zmudka K, Tracz W. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Kardiol Pol. 2009;67:591-598.
22. Blombäck B. Fibrinogen and fibrin: proteins with complex roles in hemostasis and thrombosis. Thromb Res. 1996;83:1-75. (Pubitemid 26274439)
23. Wolberg AS. Plasma and cellular contributions to fibrin network formation, structure and stability. Haemophilia. 2010;16(suppl 3):7-12.
24. Undas A, Topór-Madry R, Tracz W, Pasowicz M. Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. Thromb Haemost. 2009;102:1289-1291.
25. Nälsén C, Vessby B, Berglund L, Uusitupa M, Hermansen K, Riccardi G, Rivellese A, Storlien L, Erkkilä A, Ylä-Herttuala S, Tapsell L, Basu S. Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2β in healthy humans. J Nutr. 2006;136:1222-1228.
26. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med. 2003;35:772-781. (Pubitemid 37329480)
27. Park Y, Nam S, Yi HJ, Hong HJ, Lee M. Dietary n-3 polyunsaturated fatty acids increase oxidative stress in rats with intracerebral hemorrhagic stroke. Nutr Res. 2009;29:812-818.
28. Patrono C, Falco A, Davi G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol. 2005;5:198-203. (Pubitemid 40378753)
29. Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Medicinal Chem. 2008;6:161-180.
30. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariëns RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood. 2010;115:3980-3988.
31. Amelot AA, Tagzirt M, Ducouvret G, Kuenk L, Le Bonniec BH. Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin. J Biol Chem. 2007;282:710-720. (Pubitemid 47076616)
32. Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary heart disease. J Thromb Haemost. 2006;4:973-975.
33. Undas A, Plicner D, Stepień E, Drwiła R, Sadowski J. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein (a) and homocysteine. J Thromb Haemost. 2007;5:1988-1890.
34. Undas A, Topor-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn. 2009;119:354-359.
35. Wohner N. A role of cellular elements in thrombus formation and dissolution. Cardiovasc Hematol Agents Medicinal Chem. 2008;6:224-228.